Features China Introduction

Total Page:16

File Type:pdf, Size:1020Kb

Features China Introduction Features China Introduction Tom Blundell (President, the Biochemical Society) This issue of The Biochemist is focused on biochemistry in China. It is timely because it reflects the history of biochemical research collaboration between Chinese and UK scientists, not only by looking back over the last century, but also by reviewing some of the strengths of biochemical research in China in 2011. Downloaded from http://portlandpress.com/biochemist/article-pdf/33/5/4/3914/bio033050004.pdf by guest on 27 September 2021 It has been a busy year for the Biochemical Society, which both in the UK and China. But there were interactions is celebrating its first century. It will do so at the Centenary before Needham became involved. In this issue, Randy Celebration event at the Royal Society in London in Poon draws our attention to one of these, the first paper December, but it has already done so very impressively in from China published in a journal of the Biochemical Shanghai in May with a Joint Sino–UK Protein Symposium. Society. In 1926 Ernest Tso of the Peking Union Medical There we heard about truly momentous contributions College described vitamins in preserved duck eggs, arising from interactions of influential scientists from maintaining they are “as much used on the table as is both China and UK during the last century. Just before cheese in Western countries”. the Symposium, also in May 2011, the Biochemical Journal We should also celebrate Wang Ying-Lai, who did his opened its China office in Beijing with a mini-symposium. PhD in Cambridge between 1938 and 1941. He returned Both events are described in this issue by Frances van to China in 1945 and rose to be Director of Shanghai Klaveren and colleagues. Institute of Biochemistry. He was one of the founders of Joseph Needham, the Cambridge biochemist and biochemistry in China. Together with Zou Chenglu, who historian of science in China, is often acknowledged as the did his PhD in Biochemistry in Cambridge a decade later, person who first encouraged interactions between UK and and was influenced by Fred Sanger there, he initiated China. He spent many years in China during the Second a project to synthesize insulin. I am told they were World War and has been a huge influence on many of us, encouraged by remarks of Frederick Engels, who opined, “proteins are the mode of existence of life” and “If you know the formula of something, synthesize it”. Wang and Zou knew that Sanger had determined the sequence of insulin – the formula was known! Starting in 1958, Wang and Zou led a team of scientists from the Institute of Biochemistry in Shanghai and the Department of Chemistry in Peking University, with the ambitious task of synthesizing insulin. This was achieved by 1965, in parallel with work in Aachen and in New York – a truly amazing achievement given the Chinese had to synthesize individual amino acids. In China, a brilliant young biochemist, Zhang You-Shang, went a step further, working out how to achieve the proper joining of the disulfide bonds. A visit by Dorothy Hodgkin to Shanghai convinced the Chinese biochemists that crystallization of synthetic insulin would be an excellent further proof that the synthetic insulin was properly folded. As a result of Dorothy Hodgkin’s visit, a young crystallographer, Liang Dong-Cai, was sent to the UK, first to London to work with Charlie Bunn on protein crystallography at the Royal Institution, and then to Oxford to work in Dorothy’s laboratory on insulin. As a young graduate student in the Department in Oxford, I was fortunate to meet Dong-Cai and talk about both Joseph Needham science and China. I remember walking down South Parks 4 October 2011 © 2011 The Biochemical Society China Features Road in excited discussion with Dong-Cai on the then recent history and the new developments, which were emerging as a Cultural Revolution. Dong-Cai went back to China full of enthusiasm for progress in his country. As it happened, the work on insulin became one of the major themes of Chinese science in the period of the Cultural Revolution. Dong-Cai and his colleagues solved the structure of zinc–insulin independently using methods complementary to those used in our laboratory in Oxford and published in 1969. At that time, publications were not encouraged in China, and it took us some time in Oxford to discover the Downloaded from http://portlandpress.com/biochemist/article-pdf/33/5/4/3914/bio033050004.pdf by guest on 27 September 2021 beautiful work completed in Beijing. Dorothy Hodgkin visited Beijing in 1972; Guy and Eleanor Dodson first and then the rest of our insulin team were able to meet up with the Chinese group a few years later and enjoy the wonders of the achievements in both countries. I was lucky to spend 2 weeks giving talks and having discussions every day in the Institute of Biophysics. Dong-Cai later became Pudong skyline, Shanghai Director of the Institute of Biophysics in Beijing following Zou Chenglu. Our visits and exchanges continued over the similar enthusiasm for synthetic biology. As Pei, Schmidt 30 years since then. Dave Stuart and Andy Hemming both and Wei describe in this issue, current research activities spent time in the Institute in Beijing, and Sarah Perrett, are focused on developing useful applications in biofuels, after working in Cambridge, became a Professor in the bio-based chemicals, bioremediation and novel medicine Institute. An account of her work there on amyloids is to as well as learning more about biological systems. China be found in this issue. And it is very appropriate that Sarah is already an international player. And there are studies draws attention to the work on folding of insulin, which to investigate whether there is adequate current research interestingly went on in parallel to that by Nobel Laureate regulation on synthetic biology. The public is beginning Chris Anfinsen in the USA. to be interested since the first ‘synthetic cell’ caught their Modern biochemistry in China is moving fast, but attention in 2010. Workshops on biosafety and ethical proteins are still a continuing focus. The Chinese have issues have been recently held in China. made huge investments in second-generation protein As in the UK, the Government in China is expecting sequencing. They have also invested in other ‘big science’, much from the biochemistry and other biosciences in as readers will see in the article by Zhang and He on their drive towards wealth creation. When I went first to proteomics. After all, alternative splicing of genes and Shanghai more than 30 years ago, Pudong was marshland. post-translational modifications such as glycosylation or In 2002, I found Pudong New Area, a huge science park. phosphorylation give rise to many more proteins than I was tempted to move a branch of our company Astex there are genes. But cell systems are even more complex Therapeutics there, but we felt it would have defocused as Wu and Zhang describe in their review on autophagy our efforts in Cambridge. But now I wonder whether we in China. This lysosome-mediated process of intracellular missed an opportunity. As the Joint Sino–UK symposium degradation plays an important role in a wide variety of in May in Shanghai demonstrated, and this issue of The physiological processes such as adaptation to various Biochemist illustrates well, China and the UK are both metabolic stress and removal of pathogens. It is not aware that biochemistry will not only inform developments surprising that dysregulated autophagy activity is linked to of biologics, bioenergy, new crops and new medicines, but various pathological diseases such as neurodegeneration will also be the source of new wealth creation. The UK and tumorigenesis. will gain much from continuing its collaboration with But these advances in Chinese biochemistry and China during the coming 100 years, just as it has done especially in their applications to health, sustainable food impressively during the last century. ■ production and wealth creation have long been on the agenda. In 1993, I was a guest of the Chinese Academy Sir Tom Blundell was one of the speakers at the recent of Sciences and toured new laboratories throughout Biochemical Society Joint Sino-UK Meeting. Reviews by the country to look at the development of genetic speakers at this meeting will be published this year in modification of food crops in China. I was astonished by volume 39 (part 5) of Biochemical Society Transactions the advances being made. Nearly 20 years later, there is (www.biochemsoctrans.org) October 2011 © 2011 The Biochemical Society 5.
Recommended publications
  • ANNUAL REVIEW 1 October 2005–30 September
    WELLCOME TRUST ANNUAL REVIEW 1 October 2005–30 September 2006 ANNUAL REVIEW 2006 The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. It funds innovative biomedical research, in the UK and internationally, spending around £500 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing. www.wellcome.ac.uk THE WELLCOME TRUST The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. 123 CONTENTS BOARD OF GOVERNORS 2 Director’s statement William Castell 4 Advancing knowledge Chairman 16 Using knowledge Martin Bobrow Deputy Chairman 24 Engaging society Adrian Bird 30 Developing people Leszek Borysiewicz 36 Facilitating research Patricia Hodgson 40 Developing our organisation Richard Hynes 41 Wellcome Trust 2005/06 Ronald Plasterk 42 Financial summary 2005/06 Alastair Ross Goobey 44 Funding developments 2005/06 Peter Smith 46 Streams funding 2005/06 Jean Thomas 48 Technology Transfer Edward Walker-Arnott 49 Wellcome Trust Genome Campus As at January 2007 50 Public Engagement 51 Library and information resources 52 Advisory committees Images 1 Surface of the gut. 3 Zebrafish. 5 Cells in a developing This Annual Review covers the 2 Young children in 4 A scene from Y fruit fly. Wellcome Trust’s financial year, from Kenya. Touring’s Every Breath. 6 Data management at the Sanger Institute. 1 October 2005 to 30 September 2006. CONTENTS 1 45 6 EXECUTIVE BOARD MAKING A DIFFERENCE Developing people: To foster a Mark Walport The Wellcome Trust’s mission is research community and individual Director to foster and promote research with researchers who can contribute to the advancement and use of knowledge Ted Bianco the aim of improving human and Director of Technology Transfer animal health.
    [Show full text]
  • Functional Effects Detailed Research Plan
    GeCIP Detailed Research Plan Form Background The Genomics England Clinical Interpretation Partnership (GeCIP) brings together researchers, clinicians and trainees from both academia and the NHS to analyse, refine and make new discoveries from the data from the 100,000 Genomes Project. The aims of the partnerships are: 1. To optimise: • clinical data and sample collection • clinical reporting • data validation and interpretation. 2. To improve understanding of the implications of genomic findings and improve the accuracy and reliability of information fed back to patients. To add to knowledge of the genetic basis of disease. 3. To provide a sustainable thriving training environment. The initial wave of GeCIP domains was announced in June 2015 following a first round of applications in January 2015. On the 18th June 2015 we invited the inaugurated GeCIP domains to develop more detailed research plans working closely with Genomics England. These will be used to ensure that the plans are complimentary and add real value across the GeCIP portfolio and address the aims and objectives of the 100,000 Genomes Project. They will be shared with the MRC, Wellcome Trust, NIHR and Cancer Research UK as existing members of the GeCIP Board to give advance warning and manage funding requests to maximise the funds available to each domain. However, formal applications will then be required to be submitted to individual funders. They will allow Genomics England to plan shared core analyses and the required research and computing infrastructure to support the proposed research. They will also form the basis of assessment by the Project’s Access Review Committee, to permit access to data.
    [Show full text]
  • Cambridge University Reporter Special Number 3
    2 OFFICERS NUMBER–MICHAELMAS TERM 2000 SPECIAL NO.3 PA RT I Chancellor: H.R.H. The Prince PHILIP, Duke of Edinburgh, T Vice-Chancellor: Prof. Sir Alec BROERS, CHU Deputy Vice-Chancellors: for –,A.M.LONSDALE, NH,O.S.O’NEILL, N,Q.R.D.SKINNER, CHR, D. E. NEWLAND, SE, Prof. D. H. MELLOR, DAR Pro-Vice-Chancellors: ,A.M.LONSDALE, NH, June , D. H. MELLOR, DAR, Dec. High Steward: Vacant Deputy High Steward: , The Rt Hon. Lord RICHARDSON, CAI Commissary: , The Rt Hon. Lord OLIVER, TH Proctors for ‒: F. H. KING, M Deputy: C. A. T. MALONE, NH R. J. STIBBS, DOW Deputy: S. A. T. REDFERN, JE Orator: ,A.J.BOWEN, JE Registrary: ,T.J.MEAD, W Deputy Registrary: ,N.J.B.A.BRANSON, DAR Secretary General of the Faculties: ,D.A.LIVESEY, EM Deputy Secretary General of the Faculties: ,G.P.ALLEN, W Librarian: ,P.K.FOX, SE Deputy Librarians: ,D.J.HALL, W , A. MURRAY, W Treasurer: ,J.M.WOMACK, TH Director of the Fitzwilliam Museum and Marlay Curator: ,D.D.ROBINSON, CL Development Director: Vacant Esquire Bedells: ,J.P.EMMINES, PET ,J.H.WILLIAMS, HH University Advocate: ,N.M.PADFIELD, F, Deputy University Advocate: ,P.J.ROGERSON, CAI, OFFICERS IN INSTITUTIONS PLACED UNDER THE SUPERVISION OF THE GENERAL BOARD PROFESSORS Aeronautical Engineering, Francis Mond W. N. D AWES, CHU Aerothermal Technology Vacant African History J. I LIFFE, JN American History, Paul Mellon A. J. BADGER, SID American History and Institutions, Pitt Vacant Anatomy W.A. HARRIS, CL Anaesthesia D. K. MENON Ancient History M.
    [Show full text]
  • Crystal Structures of Native and Inhibitedforms of Human Cathepsin
    Proc. Natl. Acad. Sci. USA Vol. 90, pp. 6796-6800, July 1993 Biochemustry Crystal structures of native and inhibited forms of human cathepsin D: Implications for lysosomal targeting and drug design (aspartic protcase/N-linked oligosaccharide/pepstatin A) ERic T. BALDWIN*, T. NARAYANA BHAT*, SERGEI GULNIK*, MADHUSOODAN V. HOSUR*t, RAYMOND C. SOWDER Il, RAUL E. CACHAU*, JACK COLLINS*, ABELARDO M. SILVA*, AND JOHN W. ERICKSON*§ *Structural Biochemistry Program, Frederick Biomedical Supercomputing Center and tAIDS Vaccine Program, Program Resources Inc./DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD 21702 Communicated by David R. Davies, March 24, 1993 (receivedfor review February 4, 1993) ABSTRACT Cathepsin D (EC 3.4.23.5) is a lysosomal duced in the vicinity of the growing tumor, may degrade the protease suspected to play important roles in protein catabo- extracellular matrix and thereby promote the escape of lism, antigen processing, degenerative diseases, and breast cancer cells to the lymphatic and circulatory systems and cancer progresson. Determination of the crystal structures of enhance the invasion of new tissues (17, 18). The design of cathepsin D and a complex with pepstatin at 2.5 A resolution potent and specific inhibitors of cathepsin D will aid the provides insights into inhibitor binding and lysosomal targeting further elucidation of the roles of this enzyme in human for this two-chain, N-glycosylated aspartic protease. Compar- disease. We previously described the purification and crys- ison with the structures of a complex of pepstatin bound to tallization ofhuman cathepsin D from liver (3); similar studies rhizopuspepsin and with a human renin-bihbitor complex have been reported recently for cathepsin D isolated from revealed differences in subsite structures and inhibitor-enzyme bovine liver (19) and human spleen (20).
    [Show full text]
  • Part I Officers in Institutions Placed Under the Supervision of the General Board
    2 OFFICERS NUMBER–MICHAELMAS TERM 2009 [SPECIAL NO.7 PART I Chancellor: H.R.H. The Prince PHILIP, Duke of Edinburgh, T Vice-Chancellor: 2003, Prof. ALISON FETTES RICHARD, N, 2010 Deputy Vice-Chancellors for 2009–2010: Dame SANDRA DAWSON, SID,ATHENE DONALD, R,GORDON JOHNSON, W,STUART LAING, CC,DAVID DUNCAN ROBINSON, M,JEREMY KEITH MORRIS SANDERS, SE, SARAH LAETITIA SQUIRE, HH, the Pro-Vice-Chancellors Pro-Vice-Chancellors: 2004, ANDREW DAVID CLIFF, CHR, 31 Dec. 2009 2004, IAN MALCOLM LESLIE, CHR, 31 Dec. 2009 2008, JOHN MARTIN RALLISON, T, 30 Sept. 2011 2004, KATHARINE BRIDGET PRETTY, HO, 31 Dec. 2009 2009, STEPHEN JOHN YOUNG, EM, 31 July 2012 High Steward: 2001, Dame BRIDGET OGILVIE, G Deputy High Steward: 2009, ANNE MARY LONSDALE, NH Commissary: 2002, The Rt Hon. Lord MACKAY OF CLASHFERN, T Proctors for 2009–2010: JEREMY LLOYD CADDICK, EM LINDSAY ANNE YATES, JN Deputy Proctors for MARGARET ANN GUITE, G 2009–2010: PAUL DUNCAN BEATTIE, CC Orator: 2008, RUPERT THOMPSON, SE Registrary: 2007, JONATHAN WILLIAM NICHOLLS, EM Librarian: 2009, ANNE JARVIS, W Acting Deputy Librarian: 2009, SUSANNE MEHRER Director of the Fitzwilliam Museum and Marlay Curator: 2008, TIMOTHY FAULKNER POTTS, CL Director of Development and Alumni Relations: 2002, PETER LAWSON AGAR, SE Esquire Bedells: 2003, NICOLA HARDY, JE 2009, ROGER DERRICK GREEVES, CL University Advocate: 2004, PHILIPPA JANE ROGERSON, CAI, 2010 Deputy University Advocates: 2007, ROSAMUND ELLEN THORNTON, EM, 2010 2006, CHRISTOPHER FORBES FORSYTH, R, 2010 OFFICERS IN INSTITUTIONS PLACED UNDER THE SUPERVISION OF THE GENERAL BOARD PROFESSORS Accounting 2003 GEOFFREY MEEKS, DAR Active Tectonics 2002 JAMES ANTHONY JACKSON, Q Aeronautical Engineering, Francis Mond 1996 WILLIAM NICHOLAS DAWES, CHU Aerothermal Technology 2000 HOWARD PETER HODSON, G Algebra 2003 JAN SAXL, CAI Algebraic Geometry (2000) 2000 NICHOLAS IAN SHEPHERD-BARRON, T Algebraic Geometry (2001) 2001 PELHAM MARK HEDLEY WILSON, T American History, Paul Mellon 1992 ANTHONY JOHN BADGER, CL American History and Institutions, Pitt 2009 NANCY A.
    [Show full text]
  • Iisc-Alumni Association- M.Vijayan Lecture. Cross Fertilisation: How
    IISc-Alumni Association- M.Vijayan Lecture. Cross Fertilisation: How Crystallography has built on Mathematics. Eleanor Dodson 17th August 2017 Nostalgia time: I cannot resist revisiting old photographs! Oxford 1968? Wedding Day – July 1969 DCH building first insulin model Vijayan lost in shadows? Oxford lab - 1969 Britishx5, Indian, NZ, Aust. David Phillips, Dorothy, Tony North, Thomas, Vijaya, Tom Blundell, Ted Baker, EJD Bangalore – 1970? Bangalore 1970s Kalyani, Vijayan, Tom Blundell -1975? Bangalore – 1979-80. Vijanan Davi Kalyani Bangalore 2007: Guy's 70th Birthday Cake Workshop 2008 DCH & Siv Ramasechan – 1965 our Anomalous Dispersion Guru First anomalous data measurements done in Oxford ~ 1960 on B12 derivative by K. Venkatesan Validation: More Thought Experiments: G.N. Ramachandran Mathematics in the Service of Science? Michael Mosley -BBC 2010 “Knowledge leaps forward when brilliant experiments are analysed by independent minds.” He was referring to the discovery that Mars moves in an elliptical orbit around the sun – established by Johannes Kepler -1599 using the observations of Tycho Brahe. Mathematics in the Service of Crystallography? Structure Solution exploits: Fundamental Mathematical concepts (Some elegant, but restricted to 3D for structure, and 2D for diffraction) Technical Mathematics and Computation (messy and very easy to get wrong!) Statistics (Much needed but messy too) Why crystallography? Quote: DCH: I also first learnt at the same time about biochemistry which provided me with the molecules it seemed most desirable to 'see'. …[The] great advantage of X-ray analysis as a method of chemical structure analysis is its power to show some totally unexpected and surprising structure and to do so with absolute certainty….
    [Show full text]
  • Physiologynews
    PHYSIOLOGYNEWS winter 2005 | number 61 Meetings UCL Images of Oxford Bristol revisited Also featuring: Physiology in space Richard Naftalin’s ‘desert island’ selection Cutting through the melatonin hype Reflections of a ex-Chair Letter from Russia What turned us on to physiology Winter books special A publication of The Physiological Society OXFORD FOCUSED MEETING Ion channels, genes and regulation in smooth muscle 5-7 September 2005 More photos and a report from the Oxford Focused Meeting appear on p. 5 (photos by Prem Kumar and Roger Thomas) PHYSIOLOGYNEWS Editorial 3 Movement neuroscience at UCL Philip Harrison 4 Ion channels, genes and regulation in smooth The Society’s dog. ‘Rudolf Magnus gave muscle David Beech, Anant Parekh, Phil Aaronson 5 me to Charles Sherrington, who gave me ‘Stan-power’ 7 to Henry Dale, who gave me to the Judy Harris Physiological Society in October 1942’ Bristol revisited Austin Elliott 8 My 10 key papers 10 My top 10 papers on biological salt, water and sugar transport Published quarterly by the Physiological Society Richard Naftalin Contributions and Queries Executive Editor A week in the life of... 14 Linda Rimmer A short month in the life of the Vice Chair Ian McGrath The Physiological Society Publications Office P.O. Box 502 What turned me on to physiology? Thelma Lovick, 15 Cambridge CB1 0AL UK Bill Winlow, Austin Elliott Tel: +44 (0)1223 400180 Letter from...Russia Evgeny Nikolsky, Ellya Bukharaeva 17 Fax: +44 (0)1223 246858 Email: [email protected] The Society web server: http://www.physoc.org Physiology
    [Show full text]
  • 2019 Grimwade Visiting Fellow Oration
    2019 Grimwade Visiting Fellow Oration Department of Public Event Biochemistry and Molecular Biology, School of Biomedical Sciences Science, Society and Spinouts: From Genomes and Structural Biology to Drug Discovery Professor Sir Thomas Blundell, FRS FMedSci Department of Biochemistry, University of Cambridge Professor Tom Blundell is Director of Professor Blundell has developed new Research and Professor Emeritus in the approaches to structure-guided and Department of Biochemistry, University of fragment-based drug discovery. In 1999 he Cambridge, where he was previously Sir co-founded Astex Therapeutics, an oncology William Dunn Professor and Head of company that has eight drugs in clinical Department and Chair of School of trials. He has developed structure-guided Event Details Biological Sciences. He is a Fellow of the fragment-based approaches to drug Royal Society, member of the European discovery for difficult targets involving Date: Molecular Biology Organisation (EMBO), multiprotein systems and protein-protein Wednesday 25 September 2019 fellow of the Academy of Medical Sciences interactions. (UK) amongst other prestigious posts. Time: 4:00pm - 5:30pm Professor Blundell was a member of Professor Blundell has made many Margaret Thatcher’s Advisory Council on Venue: important contributions as a structural Science & Technology, Founding CEO of Bio21 Institute Auditorium biologist in understanding polypeptide Biotechnology and Biological Sciences 30 Flemington Road hormones, growth factors, receptor Research Council, Chairman, Royal Parkville activation, signal transduction, and DNA Commission on Environment, Deputy Chair Enquiries: repair. He has produced many widely used of Institute of Cancer Research and biochem- software packages for protein modelling President of UK Science Council. In 1997, he [email protected] and design and for predicting effects of was knighted for his contributions to mutations and to understand cancer & drug science and society.
    [Show full text]
  • Officers Number, Lent Term 2001: University Officers
    2 OFFICERS NUMBER–LENT TERM 2001 SPECIAL NO.12 PA RT I Chancellor: H.R.H. The Prince PHILIP, Duke of Edinburgh, T Vice-Chancellor: , Prof. Sir Alec BROERS, CHU, Deputy Vice-Chancellors: for –,A.M.LONSDALE, NH,O.S.O’NEILL, N,Q.R.D.SKINNER, CHR, D. E. NEWLAND, SE,D.H.MELLOR, DAR, Dr S. G. FLEET, DOW Pro-Vice-Chancellors: ,A.M.LONSDALE, NH, June , D. H. MELLOR, DAR, Dec. High Steward: , Dame BRIDGET OGILVIE, G Deputy High Steward: , The Rt Hon. Lord RICHARDSON, CAI Commissary: , The Rt Hon. Lord OLIVER, TH Proctors for ‒: F. H. KING, M Deputy: C. A. T. MALONE, NH* R. J. STIBBS, DOW Deputy: S. A. T. REDFERN, JE * Additional Deputy Proctor to Sept. (to act in place of Dr Malone) M. A. MESSAGE, CTH Orator: ,A.J.BOWEN, JE Registrary: ,T.J.MEAD, W Deputy Registrary: ,N.J.B.A.BRANSON, DAR Secretary General of the Faculties: ,D.A.LIVESEY, EM Deputy Secretary General of the Faculties: ,G.P.ALLEN, W Librarian: ,P.K.FOX, SE Deputy Librarians: ,D.J.HALL, W , A. MURRAY, W Treasurer: ,J.M.WOMACK, TH Director of the Fitzwilliam Museum and Marlay Curator: ,D.D.ROBINSON, CL Development Director: Vacant Esquire Bedells: ,J.P.EMMINES, PET ,J.H.WILLIAMS, HH University Advocate: ,N.M.PADFIELD, F, Deputy University Advocate: ,P.J.ROGERSON, CAI, OFFICERS IN INSTITUTIONS PLACED UNDER THE SUPERVISION OF THE GENERAL BOARD PROFESSORS Aeronautical Engineering, Francis Mond W. N. D AWES, CHU Aerothermal Technology H. P.HODSON, G African History J. I LIFFE, JN Algebraic Geometry N.
    [Show full text]
  • Diamond Gets Its Life Science Director Molecular Biophysics
    current events current events This section carries events of interest to the synchrotron radiation community. Works intended for this section should be sent direct to the Current-Events Editor ([email protected]). Diamond gets its Life Science Director Molecular Biophysics. She was elected Fellow of the Royal Society in 1990 and recently became a Dame in the Queen Elizabeth II honours Louise Johnson, David Phillips Professor in Molecular Biophysics at list. Oxford University, has joined the Diamond Light Source as Life Professor Johnson commented, "I am delighted to be joining such Science Director from 1 October 2003. Louise has taken up this an exciting scienti®c research organization. Since 1981, with the appointment while keeping her responsibilities at Oxford and will be commissioning of the UK's ®rst synchrotron facility at Daresbury, dividing her time equally between the two. synchrotron light sources have revolutionized biological research. Professor Johnson has made distinguished contributions to protein Diamond will be a signi®cant upgrade on present resources". crystallography and structural biology. Her book, Protein Crystal- lography, with Professor Sir Tom Blundell, published in 1976 by Academic Press, has been used by several generations of research students and crystallographers alike. Her research work and scienti®c Daresbury enters into collaboration with the Institute of leadership are held in high esteem internationally. Crystallography and Kurchatov Synchrotron Radiation Centre in Moscow On 29 September 2003, a Memorandum of Understanding (MOU) was signed between Daresbury, the Institute of Crystallography and Kurchatov Synchrotron Radiation Centre to promote collaboration in areas of mutual interest including synchrotron radiation science and technology, protein crystallography, structural genomics, nano- structures and nanotechnology, X-ray optics and imaging.
    [Show full text]
  • SPRING2017.Pdf
    ACA – Structure Matters www.AmerCrystalAssn.org Table of Contents 2 President’s Column 2-5 RefleXions from Canada 7-9 News from Latin America 9 YSIG Activities in New Orleans From the Editor's Desk Index of Advertisers 10-11 Update on Structural Dynamics Amy Sarjeant 2017 ACA President 12 ACA 2017 New Orleans Preview What's on the Cover 13 Corporate Members Page 14 14 What's on the Cover 15 ACA Council Officers; Appointments & Staff; Canadian Division Officers 16 ACA RefleXions Co-Editors & Staff 22017 ACA Award Winners Nominations for 2018 to Be Honored in New Orleans 17 Standing Committees 18-20 Scientific Interest Group Officers 21 U. S. National Committee for Crystallography 23-24 Net RefleXions 24-26 News & Awards 26-30 Remembering Dick Marsh Christine Dunham 31-32 Highlights from 2016 Fall ACA Coun- Etter Award cil Meeting Zbigniew Dauter 32 Small Grants for Outreach Patterson Award X-ray Equipment for Donation Contributors to this Issue Helen Berman 33 ACA History Project News Rognlie Award 33-34 Space Crystal Prize James O'Brien 34 Promoting Crystallography through Coloring Wood Award 35 2016 U. S. Crystal Growing Competition 37-38 Book Reviews 39 Spotlight on Stamps Manuel Soriano-Garcia 40-45 ACA Living History – Manuel Soriano-García ACA Living History 46 AIP Niels Bohr Library & Archives Announcement 47 Puzzle Corner Nobel Laureate Sir James Fraser Stoddart 48 Future Meetings Plenary Lecturer in New Orleans Contributions to ACA RefleXions may be sent to either of the Editors: Please address matters pertaining to advertisements, membership Judith L. Flippen-Anderson [email protected] inquiries, or use of the ACA mailing list to: Thomas F.
    [Show full text]
  • HIV Protease Inhibitors Have Been One of the Big Successes of Rational Drug Design. Clare Sansom Looks at the Impact of Structur
    Drug design: HIV Molecules made to measure HIV protease inhibitors have been one of the big successes of rational drug design. Clare Sansom looks at the impact of structural biology on drug discovery PROTEIN DATA BANK DATA PROTEIN 50 | Chemistry World | November 2009 www.chemistryworld.org There are fashions in drug discovery, on this new virus. enzymes are over 300 residues In short as in many fields of technical Oroszlan had proved that a similar long and contain two copies of a development, and these even follow virus, the murine leukaemia virus, HIV protease characteristic tripeptide sequence common enough patterns to be matured by proteolytic cleavage – inhibitors – now a key necessary for enzyme activity: mapped. Gartner’s ‘hype cycle’ that is, as new virus capsules bud component of multi- aspartic acid, threonine (or serine), describes the path of a technology from an infected host cell, proteases drug HIV treatments and glycine – a trio generally referred from initial adoption, over the slice up its payload of polyproteins – are a prime example to as DTG. In contrast, the retroviral peak of inflated expectation and into individual, functional proteins of structure-based drug protease is a much smaller enzyme through the consequent trough of and enzymes. Oroszlan had also design – only 99 residues in HIV – and disillusion, until reaching its ‘plateau found that the protease cleavage HIV’s protease contains only one DTG sequence. It of productivity’, by which time it sites were resistant to all known enzymes were validated was clear from the beginning that has evolved to fit its particular niche mammalian proteases, suggesting as a potential drug target this protein could not be active as a in the market and become stable.
    [Show full text]